DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
TRANSFAL
Baseline and pharmacodynamics changes of circulating exosomal microRNAs predict early versus late progression to palbociclib plus endocrine therapy in patients with metastatic breast cancer. A sub-analysis from the PARSIFAL trial
BREAST
SABCS
2019
SLLIP
Use of comprehensive cell-free circulating tumor DNA analysis to identify genomic biomarkers in newly diagnosed advanced non-small cell lung cancer patients
LUNG
AACR
2019
PALMIRA
Palociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer : The PALMIRA trial
BREAST
ESMO
2019
DXCARTES
Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX recurrence score*(RS) 18-25 or 26-100. Analyisis of RS changes at surgery (DXCARTES trial)
BREAST
AACR
2019
NOBROLA
A two-stage simon design phase II study for non-BRCA metastatic breast cancer (MBC) patients with homologous recombination deficiency treated with olaparib single agent (NOBROLA study)
BREAST
AACR
2018
PHENOMENAL
Multicenter open-label, phase II trial to evaluate the efficacy and safety of liposomal irinotecan (nal-IRI) for progressing brain metastatases in patients with HER2-negative breast cancer (The Phenomenal study)
BREAST
SABCS 2024
2018
KELLY
A phase II study of pembrolizumab and eribulin HR-positive/HER2-negative metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes (KELLY study)
BREAST
AACR
2018
SLLIP
Homology-directed repair (HDR)-defective lung adenocarcinomas in circulating tumor DNA (ctDNA)
LUNG
ESMO
2018
PHENOMENAL
Multicenter open-label, phase II trial to evaluate the efficacy and safety of liposomal irinotecan (nal-IRI) for progressing brain metastatases in patients with HER2-negative breast cancer (The Phenomenal study)
BREAST
AACR
2018
SLLIP
Cell-Free DNA (cfDNA) testing in lung adenocarcinoma (LUAC) patients: Spanish Lung Liquid versus Invasive Biopsy Program (SLLIP)
LUNG
IASLC
2018
EXCAAPE
Phase II clinical trial of radium-223 activity in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status (EXCAAPE)
PROSTATE
ESMO
2017
PHERGAIN
Chemotherapy-ree trastuzumab and pertuzumab (PH) in HER2[+] breast cancer (BC): FDG-PET response-adapted strategy: the PHERGAIN study
BREAST
SABCS
2017
Other MEDSIR related articles
"